Pill burden in HIV infection: 20 Years of experience

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 833-840

  Krentz, Hartmut B ^a,b   Cosman, Ian ^a   Lee, Kathy ^a   Ming, Jinell Mah ^a   Gill, M John ^a,b  

^a Southern Alberta Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; NATURAL PRODUCT; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG; VITAMIN;

ADULT; AGE; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; DISEASE DURATION; DRUG USE; FEMALE; HEALTH CARE CONCEPTS; HETEROSEXUAL MALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PILL BURDEN; POLYPHARMACY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ALBERTA; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84864133148     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2076     Document Type: Article

References (43)

1. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns 2002; 46:93-108.
2. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348:383-386.
3. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998; 36:1138-1161.
4. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13:S61-S72.
5. Weidle PJ, Ganea CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr 1999; 22:498-502.
6. Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M. Medication adherence strategies for drug users with HIV/AIDS. AIDS Care 1998; 10:297-312.
7. Elzi L, Marzolini C, Furrer H, et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010; 170:57-65.
8. Katz MH. HIV/AIDS 2010. Better drugs, better technologies, and lingering problems. Arch Intern Med 2010; 170:6-8.
9. Boyd MA. Improvements in antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009; 4:194-199.
10. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr 2007; 45 Suppl 1:S14-S18.
11. Manzardo C, Zaccarelli M, Aguero F, Antinori A, Miro JM. Optimal timing and best antiretroviral regimens in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 2007; 46 Suppl 1:S9-S18.
12. Martínez E, Nelson M. Simplification of antiretroviral therapy with etravirine. AIDS Rev 2010; 12:52-59.
13. McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 2009; 14:1-12.
14. Somboonwit C, Kurtyka D, Velez AP. Abacavir and lamivudine combination. Expert Opin Drug Metab Toxicol 2009; 5:1599-1606.
15. Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-871.
16. Bentué-Ferrer D, Arvieux C, Tribut O, Ruffault A, Bellissant E. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol 2009; 5:1455-1468.
17. Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. AIDS Patient Care STDS 2009; 23:903-914.
18. Boyle C, Wilson A, Treacy G, et al. Antiretroviral regimen complexity as a predictor of adherence. J Int AIDS Soc 2010; 13 Suppl 4:P121.
19. Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV Clin Trials 2008; 9:164-176.
20. Riddler SA, Haubrich R, DiRienzo G, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
21. Horberg MA, Klein DB. An update on the use of Atripla® in the treatment of HIV in the United States. HIV AIDS (Auckl) 2010; 2:135-140.
22. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4:115-125.
23. Sax PE, Meyers JL, Mugavero MJ, Davis KL. Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the US. J Int AIDS Soc 2010; 13 Suppl 4:O3.
24. Apuzzo LG, Vaida F, Gallant JE, et al. Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr 2009; 50:267-275.
25. Clay PG. Actual medication pill burden and dosing frequency in HIV-infected patients with undetectable viral loads. J Int Assoc Physicians AIDS Care (Chic) 2004; 3:49-55.
26. Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS 2004; 18:568-586.
27. Simone MJ, Appelbaum J. HIV in older adults. Geriatrics 2008; 63:6-12.
28. Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comediciations and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15:413-423.
29. Bjerrum L, Sognarrd J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998; 54:197-202.
30. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008; 31:213-224.
31. George J, Phun Y-T, Bailey MJ, Kong DCM, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother 2004; 38:1369-1376.
32. Martin S, Wolters PL, Calabrese SK, et al. The antiretroviral regimen complexity index. A novel method of quantifying regimen complexity. J Acquir Immune Defic Syndr 2007; 45:535-544.
33. Hajjar ER, Caliero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5:345-351.
34. Grundy SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006; 5:295-309.
35. Wong CY, Chaudhry SI, Desai MM, Krumholz HM. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med 2011; 124:136-143.
36. Konstantinidis A, Letmaier M, Grohmann R, et al. Polypharmacy in psychiatric inpatients: data from amsp (arzneimittelsicherheit in der psychiatrie), a European pharmacovigilance system. Eur Psychiatry 2011; 26 Suppl 1:591.
37. Procyshyn RM, Honer WG, Wu TK, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010; 71:566-573.
38. Guimarães MD, Rocha GM, Campos LN, et al. Difficulties reported by HIV-infected patients using antiretroviral therapy in Brazil. Clinics (Sao Paulo) 2008; 63:165-172.
39. Amuha MG, Kutyabami P, Kitutu FE, Odoi-Adome R, Kalyango JN. Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci 2009; 9 Suppl 1:S8-S15.
40. Biadgilign S, Deribew A, Amberbir A, Deribe K. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: a qualitative study. SAHARA J 2009; 6:148-154.
41. Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients concomitant TB and HIV treatment: a qualitative study. BMC Public Health 2010; 10:651.
42. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (2008). (Updated 14 October 2011. Accessed 30 October 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
43. Ma A, Chen DM, Chau FM, Saberi P. Improving adherence and clinical outcomes through an HIV pharmacist's interventions. AIDS Care 2010; 22:1189-1194.